 |
|
|
| |
Changes in Markers of Liver Function in Hepatitis C Virus Genotype 1b Asian Patients With Compensated Cirrhosis Treated With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir
With Ribavirin in the ONYX-II Study
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Jeong Heo1, Yan Luo2, Wan-Long Chuang3, Jidong Jia4, Kwang-Hyub Han5, Ming-Lung Yu6, Hong Tang7, Young-Suk Lim8, Cheng-Yuan Peng9, Min Xu10, Maorong Wang11, Bo Fu2, Sarah Kopecky-Bromberg2, Niloufar Mobashery2, Lai Wei12
1Department of Internal Medicine, College of Medicine, Pusan Nati onal University and Medical Research Institute, Pusan Nati onal University Hospital, Busan, Republic of Korea; 2AbbVie Inc., North Chicago, Illinois, United States;
3Kaohsiung Medical University, Kaohsiung City, Taiwan; 4Beijing Friendship Hospital, Capital Medical University, Beijing, China; 5Yonsei University College of Medicine, Seoul, Korea (the Republic of); 7West China Hospital of Sichuan University, Chengdu, China; 6Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; 8University of Ulsan College of Medicine, Seoul, Korea (the Republic of); 9China Medical University Hospital, Taichung, Taiwan; 10Guangzhou Eighth People's Hospital, Guangzhou, China; 11Department of Infecti ous Disease, the 81st Hospital, PLA/Nanjing Jingdu Hospital, Anhui Medical University, Jiangsu Province, China; 12Peking University People's Hospital, Beijing, China
|
| |
|
|
|
|
|
